HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more
HansBiomed Corporation (042520) - Total Liabilities
Latest total liabilities as of September 2025: ₩92.52 Billion KRW
Based on the latest financial reports, HansBiomed Corporation (042520) has total liabilities worth ₩92.52 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HansBiomed Corporation - Total Liabilities Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HansBiomed Corporation Competitors by Total Liabilities
The table below lists competitors of HansBiomed Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hwaway Tech Corp Ltd
SHE:001380
|
China | CN¥849.42 Million |
|
Grab Holdings Limited Warrant
NASDAQ:GRABW
|
USA | $4.84 Billion |
|
MOIL Limited
NSE:MOIL
|
India | ₹6.02 Billion |
|
TomTom N.V
PINK:TMOAF
|
USA | $576.36 Million |
|
Golden Friends
TWO:4506
|
Taiwan | NT$5.59 Billion |
|
Skytech Inc.
TW:6937
|
Taiwan | NT$859.38 Million |
|
FD Technologies Plc
PINK:FDRVF
|
USA | $149.47 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down HansBiomed Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HansBiomed Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HansBiomed Corporation (2012–2025)
The table below shows the annual total liabilities of HansBiomed Corporation from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | ₩92.52 Billion | +69.47% |
| 2024-09-30 | ₩54.59 Billion | -24.62% |
| 2023-09-30 | ₩72.42 Billion | -15.84% |
| 2022-09-30 | ₩86.05 Billion | +1.25% |
| 2021-09-30 | ₩84.99 Billion | +18.92% |
| 2020-09-30 | ₩71.47 Billion | +42.87% |
| 2019-09-30 | ₩50.03 Billion | +88.82% |
| 2018-09-30 | ₩26.49 Billion | +0.12% |
| 2017-09-30 | ₩26.46 Billion | +47.83% |
| 2016-09-30 | ₩17.90 Billion | +99.90% |
| 2015-09-30 | ₩8.95 Billion | +80.81% |
| 2014-09-30 | ₩4.95 Billion | +22.19% |
| 2013-09-30 | ₩4.05 Billion | +34.55% |
| 2012-09-30 | ₩3.01 Billion | -- |